BofA notes that Gilead’s (GILD) Trodelvy Phase 3 EVOKE-01 trial missed its OS primary endpoint, “largely as we had expected,” adding that the second line lung study is equivalent to AstraZeneca’s (AZN) datopotamab TL01 and calling the result “a directional positive” for AstraZeneca’s datopotamab. The firm had flagged risk to the EVOKE study given AstraZeneca’s study also missed OS, noting that TL01 had dual co-primary PFS and OS endpoints, while for EVOKE-01, OS was the only primary. There is no PFS data available for Gilead, with positive PFS data the basis for AstraZeneca’s filing, added the analyst, who keeps a Buy rating on AstraZeneca shares.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on AZN:
- GLP-1 Anti-Obesity Drugs: Slim Waistlines, Fat Profits
- AstraZeneca says Imfinzi combo improved survival in carcinoma patients
- AstraZeneca reports Voydeya granted regulatory approval in Japan
- AstraZeneca price target raised to 13,400 GBp from 12,900 GBp at Morgan Stanley
- AstraZeneca downgraded to Sell from Buy at UBS